153 related articles for article (PubMed ID: 12620287)
1. Pilot study of recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein (TNFR:Fc; Enbrel) in patients with refractory multiple myeloma: increase in plasma TNF alpha levels during treatment.
Tsimberidou AM; Waddelow T; Kantarjian HM; Albitar M; Giles FJ
Leuk Res; 2003 May; 27(5):375-80. PubMed ID: 12620287
[TBL] [Abstract][Full Text] [Related]
2. A pilot study of the recombinant soluble human tumour necrosis factor receptor (p75)-Fc fusion protein in patients with myelodysplastic syndrome.
Maciejewski JP; Risitano AM; Sloand EM; Wisch L; Geller N; Barrett JA; Young NS
Br J Haematol; 2002 Apr; 117(1):119-26. PubMed ID: 11918541
[TBL] [Abstract][Full Text] [Related]
3. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma.
Alexandrakis MG; Passam FH; Boula A; Christophoridou A; Aloizos G; Roussou P; Kyriakou DS
Ann Hematol; 2003 Jan; 82(1):19-23. PubMed ID: 12574959
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human soluble tumor necrosis factor (TNF) receptor (p75) fusion protein Enbrel in patients with refractory hematologic malignancies.
Tsimberidou AM; Thomas D; O'Brien S; Andreeff M; Kurzrock R; Keating M; Albitar M; Kantarjian H; Giles F
Cancer Chemother Pharmacol; 2002 Sep; 50(3):237-42. PubMed ID: 12203106
[TBL] [Abstract][Full Text] [Related]
5. A phase II study of etanercept (Enbrel), a tumor necrosis factor alpha inhibitor in patients with metastatic breast cancer.
Madhusudan S; Foster M; Muthuramalingam SR; Braybrooke JP; Wilner S; Kaur K; Han C; Hoare S; Balkwill F; Talbot DC; Ganesan TS; Harris AL
Clin Cancer Res; 2004 Oct; 10(19):6528-34. PubMed ID: 15475440
[TBL] [Abstract][Full Text] [Related]
6. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.
Drugs R D; 1999 Jan; 1(1):75-7. PubMed ID: 10565993
[No Abstract] [Full Text] [Related]
7. Are angiogenic factors, cytokines, and soluble adhesion molecules prognostic factors in patients with renal cell carcinoma?
Dosquet C; Coudert MC; Lepage E; Cabane J; Richard F
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2451-8. PubMed ID: 9815646
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human tumor necrosis factor receptor (p75) Fc fusion protein (TNFR:Fc) in rheumatoid arthritis.
Murray KM; Dahl SL
Ann Pharmacother; 1997 Nov; 31(11):1335-8. PubMed ID: 9391689
[TBL] [Abstract][Full Text] [Related]
9. Circulating hepatocyte growth factor levels in multiple myeloma.
Jakob C; Fleissner C; Zavrski I; Heider U; Possinger K; Sezer O
Br J Haematol; 2003 May; 121(3):532. PubMed ID: 12716383
[No Abstract] [Full Text] [Related]
10. Efficacy of the farnesyl transferase inhibitor R115777 in chronic myeloid leukemia and other hematologic malignancies.
Cortes J; Albitar M; Thomas D; Giles F; Kurzrock R; Thibault A; Rackoff W; Koller C; O'Brien S; Garcia-Manero G; Talpaz M; Kantarjian H
Blood; 2003 Mar; 101(5):1692-7. PubMed ID: 12411300
[TBL] [Abstract][Full Text] [Related]
11. Etanercept. Soluble tumour necrosis factor receptor, TNF receptor fusion protein, TNFR-Fc, TNR 001, Enbrel.
Drugs R D; 1999 Mar; 1(3):258-61. PubMed ID: 10566040
[No Abstract] [Full Text] [Related]
12. Production of proangiogenic cytokines during thalidomide treatment of multiple myeloma.
Dmoszyńska A; Bojarska-Junak A; Domański D; Roliński J; Hus M; Soroka-Wojtaszko M
Leuk Lymphoma; 2002 Feb; 43(2):401-6. PubMed ID: 11999576
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.
Deswal A; Bozkurt B; Seta Y; Parilti-Eiswirth S; Hayes FA; Blosch C; Mann DL
Circulation; 1999 Jun; 99(25):3224-6. PubMed ID: 10385494
[TBL] [Abstract][Full Text] [Related]
14. Response to thalidomide in progressive multiple myeloma is not mediated by inhibition of angiogenic cytokine secretion.
Neben K; Moehler T; Kraemer A; Benner A; Egerer G; Ho AD; Goldschmidt H
Br J Haematol; 2001 Dec; 115(3):605-8. PubMed ID: 11736942
[TBL] [Abstract][Full Text] [Related]
15. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood.
Di Raimondo F; Azzaro MP; Palumbo G; Bagnato S; Giustolisi G; Floridia P; Sortino G; Giustolisi R
Haematologica; 2000 Aug; 85(8):800-5. PubMed ID: 10942925
[TBL] [Abstract][Full Text] [Related]
16. Effect of etanercept (Enbrel) on interleukin 6, tumor necrosis factor alpha, and markers of immune activation in HIV-infected subjects receiving interleukin 2.
Sha BE; Valdez H; Gelman RS; Landay AL; Agosti J; Mitsuyasu R; Pollard RB; Mildvan D; Namkung A; Ogata-Arakaki DM; Fox L; Estep S; Erice A; Kilgo P; Walker RE; Bancroft L; Lederman MM
AIDS Res Hum Retroviruses; 2002 Jun; 18(9):661-5. PubMed ID: 12079562
[TBL] [Abstract][Full Text] [Related]
17. The combination of intermediate doses of thalidomide and dexamethasone reduces bone marrow micro-vessel density but not serum levels of angiogenic cytokines in patients with refractory/relapsed multiple myeloma.
Hatjiharissi E; Terpos E; Papaioannou M; Hatjileontis C; Kaloutsi V; Galaktidou G; Gerotziafas G; Christakis J; Zervas K
Hematol Oncol; 2004 Dec; 22(4):159-68. PubMed ID: 15991268
[TBL] [Abstract][Full Text] [Related]
18. Pilot study of recombinant human soluble tumor necrosis factor receptor (TNFR:Fc) in patients with low risk myelodysplastic syndrome.
Rosenfeld C; Bedell C
Leuk Res; 2002 Aug; 26(8):721-4. PubMed ID: 12191566
[TBL] [Abstract][Full Text] [Related]
19. Soluble TNF receptor fusion protein (etanercept) for the treatment of myelodysplastic syndrome: a pilot study.
Deeg HJ; Gotlib J; Beckham C; Dugan K; Holmberg L; Schubert M; Appelbaum F; Greenberg P
Leukemia; 2002 Feb; 16(2):162-4. PubMed ID: 11840280
[TBL] [Abstract][Full Text] [Related]
20. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.
Sprott H; Glatzel M; Michel BA
Rheumatology (Oxford); 2004 Apr; 43(4):524-6. PubMed ID: 15024139
[No Abstract] [Full Text] [Related]
[Next] [New Search]
